Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Product Highlight - Fluarix Tetra

30 Nov 2017

Fluarex Tetra - Inactivated quadrivalent influenza vaccine (split virion) vaccine (inj) 0.5 mL - GlaxoSmithKline

Flu vaccines help protect millions, but do you know there is a coverage gap?1
Choose Fluarix Tetra for your patients

  • The gap in B strain coverage from TIVs* can leave your patients unprotected.2,3,4,5
  • QIVs* can help to close the B strain coverage gap6,7
  • Fluarix Tetra is a QIV* which is generally well tolerated, is easy to administer, helps to increase protection against influenza B over TIVs*, closes the coverage gap to protect your patients and has robust data in high risk patients group6,8

*TIV: Trivalent Influenza Vaccine,QIV: Quadrivalent Influenza Vaccine

References:
1. United States Centers for Disease Control and Prevention. Quadrivalent Influenza Vaccine. Available at: https://www.cdc.gov/flu/protect/vaccine/quadrivalent.htm. Accessed on:3March 2017
2. Ambrose CS, Levin MJ. The rationale for quadrivalent infuenza vaccines Hum Vaccin Immunother 2012;8: 81-88
3. Jumat MR, et al. Genetic characterisation of in_uenza B viruses detected in Singapore, 2004 to 2009 BMC Res Notes 2014;7: 863
4. Belshe RB. The need for quadrivalent vaccine against seasonal influenza Vaccine 2010;28: D45–D53 5. Reed C, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine Vaccine 2012;30: 1993-1998
6. GSK. Fluarix Tetra Quadrivalent influenza vaccine (split virion, inactivated). (2017).
7. Domachowske JB, Pankow-Culot H, Bautista M et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis. 2013; 207: 1878–1887.
8. Kieninger D, Sheldon E, Lin W, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged 18 years. BMC Infectious Diseases 2013; 13:343.

Further information is available in section 12b, New in This Issue and mims.com.
Full prescribing information is available upon request.                        

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.